A cute exacerbations of chronic obstructive pulmonary disease (AECOPD), also known as 'lung attacks', are the fourth leading cause of death globally and are the leading cause of hospital admissions in Canada. Following admission for an AECOPD, there is a significant relapse rate, with up to 18% of patients being readmitted within one year (1, 2) . In Canada, the overall direct economic burden of this disease has been estimated to be $1.5 billion per year (3) . Given this significant burden, the Global initiative for chronic Obstructive Lung Disease (GOLD) and the Canadian Thoracic Society's COPD guidelines have been developed for the management of COPD (2, 4) . These guidelines emphasize the importance of a thorough history and physical examination as well as, in more severe exacerbations, chest x-rays, arterial blood gas (ABG) measurements and additional laboratory investigations to assess the severity of AECOPD. The use of antibiotics, oral corticosteroids and bronchodilators as treatment cornerstones have also been emphasized (4) . More recently, we have recommended better risk stratification of patients with lung attacks, with a view to improving subsequent management at the time of discharge (5) . For moderate to severe chronic COPD, there is strong evidence supporting the use of 'triple therapy' (6) . This triple therapy, which consists of a long-acting beta agonist (LABA) combined with an inhaled corticosteroid (ICD) and a long-acting anticholinergic, has been shown to reduce the risk of hospitalization from AECOPD (6) .
Quality assurance studies for the management of COPD have revealed suboptimal compliance with current clinical guidelines (7, 8) . A prospective study by Rowe et al (7) found that corticosteroids and antibiotics were used in 65% and 46% of patients, respectively, presenting to Canadian emergency departments with an AECOPD. For inpatient management, Lindenauer et al (8) found a 97% compliance rate for bronchodilators and an 85% compliance rate for systemic steroids and antibiotics for patients admitted with AECOPD.
The purpose of the present study was to assess the management of COPD at the time of admission and discharge; to determine adherence to current guidelines by respiratory physicians, emergency department (ED) physicians, internists and hospitalists; and to determine the outcomes of patients presenting with AECOPD.
Methods
All patients admitted to Vancouver General Hospital (VGH, Vancouver, British Columbia) with a diagnosis of AECOPD were identified. A retrospective chart and computer information system review was conducted. Patients seen in the ED in 2009 with a selfreported previous diagnosis of COPD and a primary discharge diagnosis of AECOPD were included in the present study. For patients with multiple visits, only the first ED visit was included. Additional hospital visits were documented as relapses if they occurred within three or BaCKGRound: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a significant cause of morbidity and mortality for patients with COPD. AECOPD are the leading cause of hospital admissions in Canada. Although multiple guidelines have been developed for the acute and chronic management of COPD, there are few quality assurance studies investigating adherence to these guidelines. Methods: A retrospective chart review of all patients admitted to a tertiary care hospital in 2009 for an AECOPD was performed. Using a standardized data abstraction tool, adherence to current guidelines across different physician groups and patient outcomes were assessed. Particular focus was centred on differences in management across physician groups. Results: Overall, 293 patients were evaluated. Of these, 82.6% were treated with one or more chronic COPD medication(s) in the community, with only 17.7% of patients treated with a long-acting inhaled anticholinergic medication. For treatment of AECOPD, 58% of patients received corticosteroids and 84% received antibiotics. Compared with general medicine and the hospitalist service, the respiratory medicine service demonstrated significantly better adherence with current treatment guidelines; however, even this was less than optimal. In addition, there was poor follow-up of patients cared for outside of the respiratory service. ConClusions: The present study identified significant care gaps in the treatment of patients admitted with AECOPD and on their discharge. Three investigators (SS, MY and JC) were trained to abstract data both from the medical charts and the hospital's computer system. A standardized data abstraction form was developed. To ensure interrater agreement, a kappa statistic was computed. Abstracted data included the following: the Canadian Triage and Acuity Scale score; Pharmanet (a province-wide universal data base providing an electronic list of prescribed medications for each patient); COPD-related medication prescribed in the ED and during admission and at discharge; use of preprinted orders; relapse rates; salbutamol at discharge; documented follow-up; patient smoking habits, forced expiratory volume in 1 s (FEV 1 ) measurements; and ABG values. One of the reviewers (SS) was a study investigator and was not blinded to the study hypothesis; however, the other two investigators were blinded.
The following information was recorded for all patients: demographic information (age, sex); mode of arrival to the ED (emergency health services or self); presence of comorbidities (heart disease, metabolic disease, skeletal disease, other diseases); smoking history (current, total pack years); COPD medications (bronchodilators, ICDs, combination therapy, antibiotics, oral corticosteroids, home oxygen); previous physicians involved in patient care (family physicians, respirologists); time of arrival to ED; Canadian Triage and Acuity Scale score; time to see ED physician; total time in ED; presence of Pharmanet printout; diagnostic evaluations (chest x-ray, ABG); involvement of a respiratory therapist; use of preprinted orders; resource intensity weights, which measure the health care resources used during hospital stay; treatment modalities (bronchodilators, ICDs, combination therapy, antibiotics, systemic corticosteroids, bilevel positive airway pressure, furosemide, intubation); disposition (admitted, discharged from ED); discharge suitability and plans; development or presence of comorbidities; and in-hospital mortality rates.
The present study was conducted with approval from the University of British Columbia Human Ethics Committee (Vancouver, British Columbia).
statistical analysis
All statistical analyses were performed using SPSS version 12.0 (IBM Corporation, USA). Categorical values were reported as counts and percentages with 95% CIs. Continuous variables were reported as means and SDs, or as medians with interquartile range, as appropriate. For comparison among three or more groups, ANOVA and χ 2 tests were used to determine statistical significance, which was set at P<0.05.
Results
The kappa values among the different data abstractors for the study variables ranged from 0.85 to 0.99.
Patient demographics and disposition (Figure 1)
A total of 350 charts were analyzed, of which 57 were excluded for reasons ranging from the subject not having a primary discharge diagnosis of AECOPD to lost chart volumes. After exclusion, a total of 293 patients remained. Seven patients were admitted directly to the ward, while the remaining 286 came through the ED. The group had a mean age of 74.2 years and 52.9% were male.
Patient characteristics (table 1)
The majority (95.5%) of subjects had a named family physician; however, only 15.4% had been documented as having been seen by a respiratory physician. Seventy-four per cent of patients had ≥1 pre-existing comorbidities, of which systemic hypertension (55.9%), diabetes mellitus (23.6%) and congestive heart failure (21.8%) were the most prevalent. Most patients (64.8%) were brought to the ED by emergency health services and 50% experienced worsening symptoms for at least 72 h before presentation.
CoPd medications on arrival to the ed (table 2)
In total, 82.6% of patients were treated with ≥1 maintenance COPD medications in the community. Fifty-eight per cent were treated with salbumatol, 40% with ipratropium, 47.1% with a combination of an ICD and a LABA, and 17.7% with tiotropium. A minority of AECOPD patients were concurrently being treated with prednisone (13.7%) and antibiotics (18.6%). 
disCussion
In the present study, we identified multiple opportunities for improvement in patient care. Patients requiring an admission to hospital for an AECOPD are those with moderate to severe COPD and should, therefore, based on results of multiple randomized controlled trials, be eligible for 'triple therapy' (6) . Although spirometry data were not available for this patient population, by virtue of hospital admission for AECOPD, this population would qualify for 'triple therapy' (6). We found that only 17.7% of patients were treated with a long-acting 
Data presented as n/n (%). AECOPD Acute exacerbation of chronic obstructive pulmonary disease; COPD Chronic obstructive pulmonary disease
anticholinergic and only 25.6% of patients were discharged on this 'triple therapy'. Given the significant economic burden of COPD to our health care system, patients should undergo a review of their medications and have treatment optimized at the time of discharge to reduce the risk of relapse and to prevent accelerated loss of lung function and future exacerbations on hospital discharge (4) . Without this optimization of therapy, relapse rates and health care costs will continue to climb. In the present study, 94% of patients presenting to the ED with an AECOPD were admitted. This admission rate is strikingly higher than the rate reported in previous studies, in which 67% of patients were admitted (7). This is consistent with previous analyses that have shown more hospital-based treatment in Canada for AECOPD compared with outpatient-based treatment in the United States (7).
Whereas adherence with chest x-rays was nearly universal in the present study, only one-half of the patients underwent ABG testing, which is consistent with rates reported in previous studies (8) . Whereas Canadian Thoracic Society COPD guidelines do not recommend the routine use of ABG measurements to risk stratify patients and monitor recovery if patients are on room air with appropriate oxygen saturations, current GOLD guidelines are less definitive (2, 4) . Furthermore, we found a scarcity in the use of spirometry testing throughout a patient's stay. Although the GOLD guidelines recommend against the routine use of spirometry in the setting of AECOPD, it may be useful to document a patient's FEV 1 before discharge to optimize COPD medications (4).
Despite the existence of preprinted orders to highlight optimal treatment of patients with AECOPD, these orders were used infrequently. For the entire cohort, 42% of patients did not receive systemic corticosteroids and 16% did not receive antibiotics. Regarding the failure to use antibiotics, our results were similar to previous studies that reported compliance rates in the 80th percentile (9) (10) (11) . Our data regarding the use of corticosteroids is also similar to a recent COPD audit that found a 15% to 40% failure rate for the use of corticosteroids during AECOPD (8) . One Danish study that examined reasons behind this lack of compliance revealed a lack of physician awareness of guidelines to be a major contributing factor (12) . Overall, only 51.8% of patients received ideal care with a bronchodilator, systemic corticosteroids and systemic antibiotics.
Relapse rates and LOS were higher among our patient population than previously reported (9,13). The primary likely reason for this was the suboptimal treatment of patients in our study population. There may also be additional factors including differences in health care practice between the public health care system in Canada and the private system in the United States. These high relapse rates significantly contribute to the economic burden that COPD places on the health care system. Previous studies have shown that patients are at the greatest risk of relapse within the first eight weeks of discharge; this further highlights the importance of appropriate discharge medications and follow-up on discharge to prevent these relapses (7) .
An interesting finding was the relatively short LOS for patients admitted to the CTU. This finding may, in part, relate to the fact that general internal medicine teams are on call every five nights and, from a logistical point of view, need to discharge patients before the next wave of admitted patients arrive at their hospital units. This practice may contribute to the shorter LOS for these patients cared for by internists but may also be a contributing factor to the high rate of readmission in this patient population. Our total sample size was not large enough to confirm this hypothesis.
Significant care gaps were also identified among general internists, respiratory physicians and hospitalists. Respiratory physicians were more likely to adhere to current guidelines for the use of corticosteroids, deep vein thrombosis prophylaxis and nebulizers; however, even these rates were not optimal. Although it is true that patients admitted under the general medicine and hospitalist services tended to have less severe AECOPD according to ABG values, Canadian Thoracic Society and GOLD guidelines recommend corticosteroids for all patients experiencing AECOPD, regardless of disease severity. Interestingly, although patients admitted to the respiratory service were somewhat sicker, the mortality rate in that cohort was lower than the other two groups of patients. Respiratory physicians also placed a significantly higher proportion of patients on appropriate 'triple therapy' on discharge. To our knowledge, the present study was the first to compare in-patient management of AECOPD among general internists, respiratory physicians and hospitalists. Given the proven efficacy of triple therapy in reducing the risk of AECOPD, it would appear that there is significant potential for improvement in the care of COPD patients on being discharged into the community. We recently strongly argued that patients admitted to hospital with an AECOPD should be better managed with risk stratification and appropriate optimization of maintenance therapy at the time of discharge (5). The present study highlights the importance of continuing education for specialists, hospitalists and family physicians to enable optimal patient care. It is not surprising that respirologists adhere better to COPD guidelines because they are the experts in their field. Venous thromboembolisms (VTE), for instance, were recently found to cause or complicate up to 25% of cases of AECOPD with previously unknown etiology compared with 8% of cases with a known etiology (14) . Given this potential for VTE to contribute to AECOPD, inpatients admitted for an AECOPD should be placed on VTE prophylaxis. The variations in management found among the groups in the present study illustrate the importance of the creation and implementation of evidence-based, preprinted orders for patient management.
The present study had several limitations. Because it was a retrospective chart review, data collection was limited to information transcribed by health care professionals in patient charts. Furthermore, only relapses to one hospital were recorded; therefore, it is possible that this may be an under-representation because several other hospitals are in close proximity.
ConClusions
The present study identified significant care gaps in the management of patients with AECOPD and stable COPD. Among different physician groups, respirologists comply with current guidelines significantly more than general internists and hospitalists; however, compliance was still not optimal. It is imperative that guidelines be followed given the large burden of COPD on our health care system. One potential way in which to improve care is through the implementation of preprinted orders for the treatment of AECOPD.
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